**Appendix Table D21. Reduction in migraine severity and symptoms in randomized controlled clinical trials that examined efficacy of topiramate in adults**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference****Risk of Bias** | **Definition of the Outcome** | **Daily Dose** | **Subjects in Active [Control] Groups** | **Mean****[Standard Deviation] with Drug** | **Mean****[Standard Deviation] with Placebo** | **Cohen Mean Difference****(95% CI)** | **Mean Difference****(95% CI)** |
| Storey, 200118Risk of bias Low | Mean migraine severity during treatment | 200mg/day | 19 [21] | 2.0 [0.4] | 2.0 [0.4] | -0.1 (-0.7 to 0.5) | 0.0 (-0.3 to 0.2) |
| Silberstein, 200941Risk of bias Low | Mean change in the rating of average daily headache severity | 100 mg/day | 165 [163] | -0.3 [0.6] | -0.2 [0.4] | -0.2 (-0.4 to 0.0) | -0.1 (-0.2 to 0.0) |
| **Change in worst daily headache severity** | **100 mg/day** | **165 [163]** | **-0.4 [0.7]** | **-0.2 [0.5]** | **-0.3 (-0.5 to -0.1)** | **-0.2 (-0.3 to -0.1)** |
| Mean decrease from baseline in the severity of nausea, photophobia, and phonophobia | 100 mg/day | 165 [163] | -0.2 [0.5] | -0.1 [0.4] | -0.2 (-0.4 to 0.0) | -0.1 (-0.2 to 0.0) |
| Mean change from baseline in the monthly frequency of nausea | 100 mg/day | 165 [163] | -3.4 [5.8] | -2.3 [5.7] | -0.2 (-0.4 to 0.0) | -1.1 (-2.3 to 0.1) |
| Mean change from baseline in the monthly rate of vomiting | 100 mg/day | 165 [163] | -1.0 [2.1] | -0.7 [2.6] | -0.1 (-0.3 to 0.1) | -0.3 (-0.8 to 0.2) |
| Mean change from baseline in the monthly frequency of photophobia | 100 mg/day | 165 [163] | -5.0 [6.4] | -3.8 [5.6] | -0.2 (-0.4 to 0.0) | -1.2 (-2.5 to 0.1) |
| Mean change from baseline in the monthly frequency of phonophobia | 100 mg/day | 165 [163] | -5.2 [6.0] | -3.6 [6.2] | -0.3 (-0.5 to 0.0) | -1.6 (-2.9 to -0.3) |

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval